• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Multicenter study of the performance of NTM Elite agar for the detection of nontuberculous mycobacteria from patients with cystic fibrosis.多中心研究 NTM Elite 琼脂在检测囊性纤维化患者中非结核分枝杆菌的性能。
Microbiol Spectr. 2024 Oct 3;12(10):e0273623. doi: 10.1128/spectrum.02736-23. Epub 2024 Aug 28.
2
An evaluation of methods for the isolation of nontuberculous mycobacteria from patients with cystic fibrosis, bronchiectasis and patients assessed for lung transplantation.评价从囊性纤维化、支气管扩张症患者以及进行肺移植评估的患者中分离非结核分枝杆菌的方法。
BMC Pulm Med. 2019 Jan 21;19(1):19. doi: 10.1186/s12890-019-0781-2.
3
Evaluation of RGM Medium for Isolation of Nontuberculous Mycobacteria from Respiratory Samples from Patients with Cystic Fibrosis in the United States.评估RGM培养基用于从美国囊性纤维化患者呼吸道样本中分离非结核分枝杆菌的效果。
J Clin Microbiol. 2017 May;55(5):1469-1477. doi: 10.1128/JCM.02423-16. Epub 2017 Feb 22.
4
Performance of RGM Medium for Isolation of Nontuberculous Mycobacteria from Respiratory Specimens from Non-Cystic Fibrosis Patients.RGM 培养基对非囊性纤维化患者呼吸道标本中非结核分枝杆菌分离的性能。
J Clin Microbiol. 2019 Jan 30;57(2). doi: 10.1128/JCM.01519-18. Print 2019 Feb.
5
Comparison of Mycobacterial Growth Indicator Tube with Culture on RGM Selective Agar for Detection of Mycobacteria in Sputum Samples from Patients with Cystic Fibrosis.分枝杆菌生长指示管与罗氏分枝杆菌选择性琼脂培养法在检测囊性纤维化患者痰液样本中分枝杆菌的比较
J Clin Microbiol. 2016 Aug;54(8):2047-50. doi: 10.1128/JCM.00630-16. Epub 2016 May 25.
6
Evaluation of Various Culture Media for Detection of Rapidly Growing Mycobacteria from Patients with Cystic Fibrosis.评估用于检测囊性纤维化患者中快速生长分枝杆菌的各种培养基
J Clin Microbiol. 2016 Jul;54(7):1797-1803. doi: 10.1128/JCM.00471-16. Epub 2016 Apr 20.
7
Improved detection of mycobacteria in CF and tissue samples grown in mycobacteria growth indicator tube incubated at 30°C compared to conventional growth conditions of liquid and solid media.与液体和固体培养基的传统培养条件相比,在30°C孵育的分枝杆菌生长指示管中培养的囊性纤维化(CF)和组织样本中,分枝杆菌的检测得到了改进。
J Clin Microbiol. 2024 Sep 11;62(9):e0068324. doi: 10.1128/jcm.00683-24. Epub 2024 Aug 13.
8
[Evaluation of blood agar medium for the growth of mycobacteria].[用于分枝杆菌生长的血琼脂培养基评估]
Mikrobiyol Bul. 2011 Oct;45(4):617-22.
9
Clinical Evaluation of Nontuberculous Mycobacteria (NTM) Elite Agar, a New Medium for the Isolation of NTM: a Multicenter Study.非结核分枝杆菌(NTM)精英琼脂的临床评估,一种用于分离 NTM 的新型培养基:一项多中心研究。
J Clin Microbiol. 2023 Apr 20;61(4):e0003623. doi: 10.1128/jcm.00036-23. Epub 2023 Mar 28.
10
Using Vitek MS v3.0 To Identify Nontuberculous Mycobacteria in Liquid Media in a Clinical Microbiology Laboratory.使用 Vitek MS v3.0 在临床微生物实验室的液体培养基中鉴定非结核分枝杆菌。
Microbiol Spectr. 2022 Dec 21;10(6):e0201822. doi: 10.1128/spectrum.02018-22. Epub 2022 Oct 26.

引用本文的文献

1
Mixed nontuberculous mycobacteria in an immunocompromised patient with probable progressive multifocal leukoencephalopathy.一名免疫功能低下且可能患有进行性多灶性白质脑病患者体内的混合性非结核分枝杆菌。
IJID Reg. 2024 Nov 29;14:100502. doi: 10.1016/j.ijregi.2024.100502. eCollection 2025 Mar.

本文引用的文献

1
Clinical Evaluation of Nontuberculous Mycobacteria (NTM) Elite Agar, a New Medium for the Isolation of NTM: a Multicenter Study.非结核分枝杆菌(NTM)精英琼脂的临床评估,一种用于分离 NTM 的新型培养基:一项多中心研究。
J Clin Microbiol. 2023 Apr 20;61(4):e0003623. doi: 10.1128/jcm.00036-23. Epub 2023 Mar 28.
2
Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases.非结核分枝杆菌肺病的共识管理推荐意见。
Lancet Infect Dis. 2022 Jul;22(7):e178-e190. doi: 10.1016/S1473-3099(21)00586-7. Epub 2022 Jan 25.
3
Decontamination Strategies Used for AFB Culture Significantly Reduce the Viability of Complex in Sputum Samples from Patients with Cystic Fibrosis.用于抗酸杆菌培养的去污策略显著降低了囊性纤维化患者痰液样本中复合物的活力。
Microorganisms. 2021 Jul 27;9(8):1597. doi: 10.3390/microorganisms9081597.
4
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.非结核分枝杆菌肺病治疗:美国胸科学会/欧洲呼吸学会/欧洲临床微生物学和传染病学会/美国感染病学会临床实践指南。
Clin Infect Dis. 2020 Aug 14;71(4):905-913. doi: 10.1093/cid/ciaa1125.
5
Comparison of the RGM medium and the mycobacterial growth indicator tube automated system for isolation of non-tuberculous mycobacteria from sputum samples of cystic fibrosis patients in Belgium.比利时用于从囊性纤维化患者痰液样本中分离非结核分枝杆菌的RGM培养基与分枝杆菌生长指示管自动化系统的比较。
J Clin Tuberc Other Mycobact Dis. 2018 Aug 1;13:1-4. doi: 10.1016/j.jctube.2018.07.003. eCollection 2018 Dec.
6
Evaluation of a novel rapidly-growing mycobacteria medium for isolation of complex from respiratory specimens from patients with bronchiectasis.一种用于从支气管扩张症患者呼吸道标本中分离复合菌的新型快速生长分枝杆菌培养基的评估。
Heliyon. 2019 Oct 24;5(10):e02684. doi: 10.1016/j.heliyon.2019.e02684. eCollection 2019 Oct.
7
An evaluation of methods for the isolation of nontuberculous mycobacteria from patients with cystic fibrosis, bronchiectasis and patients assessed for lung transplantation.评价从囊性纤维化、支气管扩张症患者以及进行肺移植评估的患者中分离非结核分枝杆菌的方法。
BMC Pulm Med. 2019 Jan 21;19(1):19. doi: 10.1186/s12890-019-0781-2.
8
Performance of RGM Medium for Isolation of Nontuberculous Mycobacteria from Respiratory Specimens from Non-Cystic Fibrosis Patients.RGM 培养基对非囊性纤维化患者呼吸道标本中非结核分枝杆菌分离的性能。
J Clin Microbiol. 2019 Jan 30;57(2). doi: 10.1128/JCM.01519-18. Print 2019 Feb.
9
Pulmonary disease by non-tuberculous mycobacteria - clinical management, unmet needs and future perspectives.非结核分枝杆菌肺病——临床管理、未满足的需求和未来展望。
Expert Rev Respir Med. 2017 Dec;11(12):977-989. doi: 10.1080/17476348.2017.1386563. Epub 2017 Oct 10.
10
Evaluation of RGM Medium for Isolation of Nontuberculous Mycobacteria from Respiratory Samples from Patients with Cystic Fibrosis in the United States.评估RGM培养基用于从美国囊性纤维化患者呼吸道样本中分离非结核分枝杆菌的效果。
J Clin Microbiol. 2017 May;55(5):1469-1477. doi: 10.1128/JCM.02423-16. Epub 2017 Feb 22.

多中心研究 NTM Elite 琼脂在检测囊性纤维化患者中非结核分枝杆菌的性能。

Multicenter study of the performance of NTM Elite agar for the detection of nontuberculous mycobacteria from patients with cystic fibrosis.

机构信息

Laboratory Medicine Department, UZ Leuven University Hospitals, Leuven, Belgium.

Department of Microbiology, Immunology, and Transplantation, Laboratory of Clinical Microbiology, KU Leuven, Leuven, Belgium.

出版信息

Microbiol Spectr. 2024 Oct 3;12(10):e0273623. doi: 10.1128/spectrum.02736-23. Epub 2024 Aug 28.

DOI:10.1128/spectrum.02736-23
PMID:39194292
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11465971/
Abstract

The performance of a novel selective agar was evaluated against the performance of conventional mycobacterial cultures, i.e., a combination of the mycobacterial growth indicator tube (MGIT) with Löwenstein-Jensen (LJ), for the detection of nontuberculous mycobacteria (NTM) in sputum samples from people with cystic fibrosis (pwCF). Two hundred eighty-three sputum samples (231 fresh sputum and 52 spiked sputum) from 143 pwCF were collected. They were inoculated without prior decontamination on NTM Elite agar (30°C ± 2°C for 28 days) and inoculated on both MGIT and LJ (35°C-37°C for 6-8 weeks) after N-acetyl-L-cysteine-2% sodium hydroxide decontamination. NTM were identified by Matrix-Assisted Laser Desorption Ionization/Time of Flight Mass Spectrometry and/or PCR, and whole-genome sequencing. A total of 67 NTM were recovered overall by the combination of all culture media. NTM Elite agar allowed the recovery of 65 NTM (97%), compared to 22 for the conventional MGIT and LJ media combination (32.8%), including 22 NTM for MGIT (32.8%) and 3 NTM with the LJ medium (4.5%). For complex, the sensitivity of NTM Elite agar was 95% compared with a sensitivity of 30% for the conventional MGIT and LJ media combination. Overall, 17.3% of cultures on NTM Elite agar were contaminated with other micro-organisms vs 46.3% on MGIT and 77% on LJ. This study shows that the novel selective agar (NTM Elite agar) significantly outperforms the conventional MGIT and LJ media combination in terms of sensitivity, selectivity, and ease of culture, without the requirement of an L3 laboratory.IMPORTANCENontuberculous mycobacteria (NTM) are significant pulmonary pathogens in patients with pre-existing structural lung conditions such as cystic fibrosis, bronchiectasis, or chronic obstructive pulmonary disease. complex and complex (MABSC) are the most frequently isolated organisms. Compared to the recommended culture method for NTM, which combines solid and liquid culture media, NTM Elite agar enables a faster/easier diagnosis and speeds up identification and susceptibility testing as the final reading is at 28 days instead of 6-8 weeks for the conventional mycobacterial cultures. In addition, for the NTM Elite agar, no decontamination stage before inoculation is necessary, unlike the conventional mycobacterial cultures. NTM Elite agar is derived from a formulation of medium adapted to rapidly growing mycobacteria (RGM). The medium enables the growth of RGM while suppressing other flora. It is supported with published clinical data showing the benefits of this medium.

摘要

新型选择性琼脂对常规分枝杆菌培养物(即分枝杆菌生长指示管(MGIT)与 Löwenstein-Jensen(LJ)的组合)的性能进行了评估,用于检测囊性纤维化(CF)患者的痰样本中的非结核分枝杆菌(NTM)。从 143 名 CF 患者中收集了 283 份痰样本(231 份新鲜痰和 52 份加标痰)。在进行 N-乙酰-L-半胱氨酸-2%氢氧化钠去污之前,它们未经预先去污即接种于 NTM Elite 琼脂(30°C±2°C,28 天)上,并在 MGIT 和 LJ 上接种(35°C-37°C,6-8 周)。通过基质辅助激光解吸/飞行时间质谱和/或 PCR 和全基因组测序鉴定 NTM。通过所有培养物总共回收了 67 株 NTM。NTM Elite 琼脂可回收 65 株 NTM(97%),而常规 MGIT 和 LJ 培养基组合可回收 22 株 NTM(32.8%),其中 22 株 MGIT(32.8%)和 3 株 LJ 培养基(4.5%)。对于 complex,NTM Elite 琼脂的灵敏度为 95%,而常规 MGIT 和 LJ 培养基组合的灵敏度为 30%。总体而言,NTM Elite 琼脂的培养物中有 17.3%被其他微生物污染,而 MGIT 为 46.3%,LJ 为 77%。这项研究表明,新型选择性琼脂(NTM Elite 琼脂)在灵敏度、选择性和培养便利性方面明显优于常规 MGIT 和 LJ 培养基组合,而无需三级实验室。

重要性

非结核分枝杆菌(NTM)是患有先前存在的结构性肺部疾病(如囊性纤维化、支气管扩张或慢性阻塞性肺疾病)的患者肺部的重要病原体。 complex 和 complex(MABSC)是最常分离到的生物体。与推荐的 NTM 培养方法(将固体和液体培养基相结合)相比,NTM Elite 琼脂能够更快/更容易地进行诊断,并加快鉴定和药敏试验,因为最终读数为 28 天,而常规分枝杆菌培养则为 6-8 周。此外,对于 NTM Elite 琼脂,与常规分枝杆菌培养物不同,在接种前不需要去污阶段。NTM Elite 琼脂源自一种改良的快速生长分枝杆菌(RGM)培养基配方。该培养基使 RGM 生长,同时抑制其他菌群。它得到了发表的临床数据的支持,这些数据显示了该培养基的益处。